Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial

IMPORTANCE: There remains an unmet need to improve clinical outcomes in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). OBJECTIVE: To evaluate clinical benefit of first-line nivolumab plus ipilimumab vs nivolumab alone in patients with R/M SCCHN. DESIG...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrington, Kevin J., Ferris, Robert L., Gillison, Maura, Tahara, Makoto, Argiris, Athanasios, Fayette, Jérôme, Schenker, Michael, Bratland, Åse, Walker, John W. T., Grell, Peter, Even, Caroline, Chung, Christine H., Redman, Rebecca, Coutte, Alexandre, Salas, Sébastien, Grant, Cliona, de Azevedo, Sergio, Soulières, Denis, Hansen, Aaron R., Wei, Li, Khan, Tariq Aziz, Miller-Moslin, Karen, Roberts, Mustimbo, Haddad, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080406/
https://www.ncbi.nlm.nih.gov/pubmed/37022706
http://dx.doi.org/10.1001/jamaoncol.2023.0147

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080406/
https://www.ncbi.nlm.nih.gov/pubmed/37022706
http://dx.doi.org/10.1001/jamaoncol.2023.0147

Ejemplares similares